Summary (tl;dr)

The Trump administration has officially reclassified certain marijuana products from Schedule I to Schedule III under federal law, marking a significant shift in U.S. drug policy that recognizes cannabis's accepted medical use and lower abuse potential.

Essential Background

Under the Controlled Substances Act of 1970, drugs are categorized into five schedules based on their accepted medical use, abuse potential, and likelihood of dependence. Historically, marijuana has been classified as a Schedule I drug, alongside substances like heroin, signifying no accepted medical use and a high potential for abuse. This classification has imposed severe restrictions on the cannabis industry, including punitive tax laws under IRS Code Section 280E and significant hurdles for scientific research. Despite federal restrictions, many U.S. states have independently moved to legalize medical and recreational marijuana, creating a complex and often contradictory legal environment.

The Full Story

On Thursday, April 23, 2026, the Trump administration announced the reclassification of FDA-approved marijuana products and marijuana products regulated under qualifying state medical marijuana licenses from Schedule I to Schedule III of the Controlled Substances Act. This action, signed by Acting Attorney General Todd Blanche, fulfills an executive order previously issued by President Trump in December 2025. The reclassification now places cannabis in a category with drugs like ketamine and anabolic steroids, acknowledging its accepted medical use and a moderate to low potential for physical and psychological dependence. While this move does not federally legalize marijuana for recreational use, it represents a substantial alteration of its federal regulatory status. Concurrently, the Justice Department is initiating an expedited administrative hearing process to explore a broader reclassification of marijuana. This development has spurred a notable increase in the stock prices of cannabis companies, including Tilray (TLRY), largely due to the anticipated removal of restrictive tax burdens and improved access to banking services.

Why It Matters

This reclassification is a pivotal policy change with far-reaching implications for the cannabis industry and medical research. Crucially, it exempts cannabis businesses from IRS Code Section 280E, which previously disallowed deductions for ordinary business expenses, leading to exceptionally high effective tax rates. This financial relief is expected to significantly bolster the profitability and stability of cannabis companies. Furthermore, the shift to Schedule III is poised to unlock expanded opportunities for medical research into cannabis, an area previously stifled by its Schedule I designation. The decision also lends federal legitimacy to state-licensed medical marijuana programs and is anticipated to ease current banking challenges faced by cannabis operators. Although it stops short of full federal legalization, this reclassification marks a critical step towards harmonizing federal drug policy with the widespread state-level acceptance of medical marijuana, potentially laying the groundwork for future reforms.

Geographic Location

• Washington, D.C., District of Columbia, United States (Justice Department announcement and executive order signing)